Thromboelastography Might Be More Applicable to Guide Anticoagulant Therapy than Fibrinolytic Therapy in Critically Ill Patients with COVID-19 - 12/01/21
Doi : 10.1016/j.jamcollsurg.2020.11.003
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| Disclosure Information: Nothing to disclose. |
|
| Disclosures outside the scope of this work: Dr Cruz is the founder of A2 Therapeutics and is supported in part by the Center for Translational Research on Inflammatory Disease (CTRID). Dr Cruz holds patent no. 7879793 for treatment of medical condition with A2 domain of Von Willebrand factor. Dr Trautner receives payment from the Agency for Healthcare Research and Quality, Department of Veterans Affairs Heal Services Research and Development, and receives grant money from Zambon Pharmaceuticals and personal fees from Paratek. |
|
| Support: Dr Brubaker is supported by NIH/National Heart, Lung, and Blood Institute grant T32 HL139425. Dr Cruz is supported by grant 01 BX002551 from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service. Dr Trautner is supported in part by the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413) at the Michael E DeBakey Veterans Affairs Medical Center, Houston, TX. |
|
| Disclaimer: The contents of this letter do not represent the views of the Department of Veterans Affairs or the US Government. |
© 2020
American College of Surgeons. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 232 - N° 2
P. 227-229 - février 2021 Retour au numéro
Article précédent
- Performing Ultrasound-Guided Percutaneous Tracheostomy in COVID-19 Patients
- Carlos Augusto Metidieri Menegozzo, Marcelo Cristiano Rocha, Edivaldo Massazo Utiyama
- Surgical Resident Burnout: Don’t Miss the Forest for the Trees
- John J. Squiers, J. Michael DiMaio
Bienvenue sur EM-consulte, la référence des professionnels de santé.